Stock comparison
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
RIGL
Rigel Pharmaceuticals
Market cap
$536.75M
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
| Strategy | HALO | RIGL | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 47D | HALO |
| Benjamin Graham | 83A | 34F | HALO |
| Philip Fisher | 65B | 54C | HALO |
| Peter Lynch | 53D | 54C | RIGL |
| Joel Greenblatt | 40D | 48D | RIGL |
| Charlie Munger | 80C | 62D | HALO |
| Terry Smith | 84A | 61C | HALO |
| Metric | HALO | RIGL |
|---|---|---|
| Market cap | $8.1B | $536.75M |
| P/E (TTM) | 24.0x | 1.4x |
| EV/EBIT | 10.2x | 4.3x |
| ROIC (TTM) | 23.65% | 27.96% |
| Gross margin | 81.24% | 93.39% |
| Net margin | 23.13% | 121.51% |
| Revenue CAGR 5y | 33.23% | 18.5% |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
RIGL leads on
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.